408 related articles for article (PubMed ID: 14585939)
1. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.
Schulman S; Wåhlander K; Lundström T; Clason SB; Eriksson H;
N Engl J Med; 2003 Oct; 349(18):1713-21. PubMed ID: 14585939
[TBL] [Abstract][Full Text] [Related]
2. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.
Francis CW; Berkowitz SD; Comp PC; Lieberman JR; Ginsberg JS; Paiement G; Peters GR; Roth AW; McElhattan J; Colwell CW;
N Engl J Med; 2003 Oct; 349(18):1703-12. PubMed ID: 14585938
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran.
Eriksson H; Lundström T; Wåhlander K; Clason SB; Schulman S;
Thromb Haemost; 2005 Sep; 94(3):522-7. PubMed ID: 16268466
[TBL] [Abstract][Full Text] [Related]
4. Ximelagatran for the secondary prevention of venous thromboembolism: a complementary follow-up analysis of the THRIVE III study.
Schulman S; Lundström T; Wålander K; Billing Clason S; Eriksson H
Thromb Haemost; 2005 Oct; 94(4):820-4. PubMed ID: 16270637
[TBL] [Abstract][Full Text] [Related]
5. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
Eriksson BI; Arfwidsson AC; Frison L; Eriksson UG; Bylock A; Kälebo P; Fager G; Gustafsson D
Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482
[TBL] [Abstract][Full Text] [Related]
6. Ximelagatran for treatment and prophylaxis of recurrent events in deep vein thrombosis.
Koscielny J; Kiesewetter H; Jörg I; Harenberg J
Clin Appl Thromb Hemost; 2007 Jul; 13(3):299-307. PubMed ID: 17636192
[TBL] [Abstract][Full Text] [Related]
7. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.
Eriksson BI; Agnelli G; Cohen AT; Dahl OE; Mouret P; Rosencher N; Eskilson C; Nylander I; Frison L; Ogren M;
Thromb Haemost; 2003 Feb; 89(2):288-96. PubMed ID: 12574809
[TBL] [Abstract][Full Text] [Related]
8. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.
Ridker PM; Goldhaber SZ; Danielson E; Rosenberg Y; Eby CS; Deitcher SR; Cushman M; Moll S; Kessler CM; Elliott CG; Paulson R; Wong T; Bauer KA; Schwartz BA; Miletich JP; Bounameaux H; Glynn RJ;
N Engl J Med; 2003 Apr; 348(15):1425-34. PubMed ID: 12601075
[TBL] [Abstract][Full Text] [Related]
9. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.
Fiessinger JN; Huisman MV; Davidson BL; Bounameaux H; Francis CW; Eriksson H; Lundström T; Berkowitz SD; Nyström P; Thorsén M; Ginsberg JS;
JAMA; 2005 Feb; 293(6):681-9. PubMed ID: 15701909
[TBL] [Abstract][Full Text] [Related]
10. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.
Kearon C; Gent M; Hirsh J; Weitz J; Kovacs MJ; Anderson DR; Turpie AG; Green D; Ginsberg JS; Wells P; MacKinnon B; Julian JA
N Engl J Med; 1999 Mar; 340(12):901-7. PubMed ID: 10089183
[TBL] [Abstract][Full Text] [Related]
11. Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran.
Harenberg J; Jörg I; Weiss C
Int J Toxicol; 2006; 25(3):165-9. PubMed ID: 16717032
[TBL] [Abstract][Full Text] [Related]
12. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Lee AY; Levine MN; Baker RI; Bowden C; Kakkar AK; Prins M; Rickles FR; Julian JA; Haley S; Kovacs MJ; Gent M;
N Engl J Med; 2003 Jul; 349(2):146-53. PubMed ID: 12853587
[TBL] [Abstract][Full Text] [Related]
13. Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty.
Colwell CW; Berkowitz SD; Lieberman JR; Comp PC; Ginsberg JS; Paiement G; McElhattan J; Roth AW; Francis CW;
J Bone Joint Surg Am; 2005 Oct; 87(10):2169-77. PubMed ID: 16203879
[TBL] [Abstract][Full Text] [Related]
14. Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran.
Harenberg J; Ingrid J; Tivadar F
Isr Med Assoc J; 2002 Nov; 4(11):1003-5. PubMed ID: 12489490
[TBL] [Abstract][Full Text] [Related]
15. Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolism.
Wåhlander K; Eriksson H; Lundström T; Billing Clason S; Wall U; Nyström P; Wessman P; Schulman S;
Br J Haematol; 2006 Apr; 133(1):68-77. PubMed ID: 16512831
[TBL] [Abstract][Full Text] [Related]
16. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V).
Halperin JL;
Am Heart J; 2003 Sep; 146(3):431-8. PubMed ID: 12947359
[TBL] [Abstract][Full Text] [Related]
17. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
Douketis JD; Arneklev K; Goldhaber SZ; Spandorfer J; Halperin F; Horrow J
Arch Intern Med; 2006 Apr; 166(8):853-9. PubMed ID: 16636210
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study.
Heit JA; Colwell CW; Francis CW; Ginsberg JS; Berkowitz SD; Whipple J; Peters G;
Arch Intern Med; 2001 Oct; 161(18):2215-21. PubMed ID: 11575978
[TBL] [Abstract][Full Text] [Related]
19. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
Leizorovicz A; Cohen AT; Turpie AG; Olsson CG; Vaitkus PT; Goldhaber SZ;
Circulation; 2004 Aug; 110(7):874-9. PubMed ID: 15289368
[TBL] [Abstract][Full Text] [Related]
20. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery.
Agnelli G; Piovella F; Buoncristiani P; Severi P; Pini M; D'Angelo A; Beltrametti C; Damiani M; Andrioli GC; Pugliese R; Iorio A; Brambilla G
N Engl J Med; 1998 Jul; 339(2):80-5. PubMed ID: 9654538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]